Food Engineering / Gıda Mühendisliği

Permanent URI for this collectionhttps://hdl.handle.net/11147/12

Browse

Filters

2018 - 201922020 - 20232

Settings

Author: search.filters.author.Johnson, RonaldPublication Index: search.filters.publicationIndex.WoS

Search Results

Now showing 1 - 4 of 4
  • Conference Object
    Decision Making on Postmastectomy Radiation Therapy for Patients With T3n0m0 Luminal Breast Cancer
    (Springer, 2023) King, Caleb; Vargo, John; Bhargava, Rohit; Diego, Emilia J.; Cowher, Michael; Johnson, Ronald; Sezgin, Efe
    [No abstract available]
  • Conference Object
    Survival Impact of Intervention To Distant Metastatic Lesions in Patients With Breast Cancer
    (Springer, 2022) Abidi, Hira; Ayoade, Oluwaseun; McAuliffe, Priscilla; Johnson, Ronald; Lee, Joanna; Keenan, Donald; Steiman, Jennifer; Sezgin, Efe; Soran, Atilla
    INTRODUCTION: Approximately 25% of patients (pts) with stage I - III breast cancer (BC) develop distant metastatic disease, a significant cause of mortality. The aim of this study is to evaluate whether intervention to metastatic lesions, in pts initially presenting with stage I–III BC, impacts overall survival (OS) and post-distant recurrence survival (PDRS). METHODS: This is a singleinstitution retrospective study of 201 pts with stage I–III BC, who subsequently develop metastatic lesions to the liver, lung, and/or bone, from 2006-2016. The cohorts included pts receiving intervention to their metastases (IM, n=100) versus no intervention to their metastases (NI, n=101). Two pts in the IM group were lost to follow up and excluded from the survival analysis. The primary study outcomes are OS and PDRS. The characteristics of the pts were compared with X2 test. OS curves were calculated by Kaplan-Meier method and multivariable analysis by Cox regression. Statistical significance was set at p< 0.05.
  • Conference Object
    Can Post-Mastectomy Radiation Therapy Be Omitted in T1-2 Clinically Node-Negative Breast Cancer Patients With a Positive Sentinel Lymph Node Biopsy?
    (Springer, 2019) Dinh, Kate; Soran, Atilla; Işık, Arda; McAuliffe, Priscilla; Diego, Emilia; Sezgin, Efe; Johnson, Ronald
    Background/Objective: The AMAROS trial demonstrated that both axillary radiation and axillary lymph node dissection (ALND) provide excellent locoregional control in patients with clinically node-negative T1-2 breast cancers and a positive sentinel lymph node biopsy (+SLNB). In that study, 18% of patients underwent total mastectomy (TM). We evaluate survival outcome of TM patients who do not require additional axillary treatment after identification of a +SLNB.
  • Article
    Citation - WoS: 260
    Citation - Scopus: 293
    Randomized Trial Comparing Resection of Primary Tumor With No Surgery in Stage Iv Breast Cancer at Presentation: Protocol Mf07-01
    (Springer, 2018) Soran, Atilla; Özmen, Vahit; Özbaş, Serdar; Karanlık, Hasan; Müslümanoğlu, Mahmut; İgci, Abdullah; Johnson, Ronald; Sezgin, Efe
    The MF07-01 trial is a multicenter, phase III, randomized, controlled study comparing locoregional treatment (LRT) followed by systemic therapy (ST) with ST alone for treatment-na < ve stage IV breast cancer (BC) patients. At initial diagnosis, patients were randomized 1:1 to either the LRT or ST group. All the patients were given ST either immediately after randomization or after surgical resection of the intact primary tumor. The trial enrolled 274 patients: 138 in the LRT group and 136 in the ST group. Hazard of death was 34% lower in the LRT group than in the ST group (hazard ratio [HR], 0.66; 95% confidence interval [CI], 0.49-0.88; p = 0.005). Unplanned subgroup analyses showed that the risk of death was statistically lower in the LRT group than in the ST group with respect to estrogen receptor (ER)/progesterone receptor (PR)(+) (HR 0.64; 95% CI 0.46-0.91; p = 0.01), human epidermal growth factor 2 (HER2)/neu(-) (HR 0.64; 95% CI 0.45-0.91; p = 0.01), patients younger than 55 years (HR 0.57; 95% CI 0.38-0.86; p = 0.007), and patients with solitary bone-only metastases (HR 0.47; 95% CI 0.23-0.98; p = 0.04). In the current trial, improvement in 36-month survival was not observed with upfront surgery for stage IV breast cancer patients. However, a longer follow-up study (median, 40 months) showed statistically significant improvement in median survival. When locoregional treatment in de novo stage IV BC is discussed with the patient as an option, practitioners must consider age, performance status, comorbidities, tumor type, and metastatic disease burden.